معرفی
Professor Asier Unciti-Broceta holds a Personal Chair in Medicinal Chemistry at the University of Edinburgh, where he leads the Innovative Therapeutics Lab at Edinburgh Cancer Research (Institute of Genetics and Cancer). He established the institute's first chemistry laboratory in 2010. His research focuses on developing novel chemical strategies to improve cancer treatment efficacy and safety, including kinase inhibitors and bioorthogonal prodrug approaches.
Education includes an MPharm (1994-1999) and PhD in Medicinal Chemistry (2000-2004) from the University of Granada, Spain, followed by postdoctoral training at the University of Edinburgh (2005-2008).
Research interests span:
- Design of selective kinase inhibitors through phenotypic screening
- Bioorthogonal prodrug activation using palladium/gold nanotechnology
- Target identification for novel cancer therapeutics
- Development of nanoparticle-based photothermal ablation techniques
Publication trends emphasize medicinal chemistry innovations in cancer drug delivery, with recurring themes of nanoparticle applications, kinase inhibition mechanisms, and bioorthogonal chemistry for targeted therapy.
Awards and honors:
- CRUK Pioneer Award (2015)
- EPSRC Healthcare Technology Challenge Award (2015)
- RSE/Patrick Neill Medal (2016)
Current research projects include UKRI-funded work on antibody-palladium conjugates (2024-2026) and Nuvectis Pharma-sponsored development of NXP900. He directs the Edinburgh Cancer Discovery Unit and mentors 7 PhD/Master's students. The Innovative Therapeutics Lab comprises 5 postdoctoral fellows and a chemistry lab manager.
